Thus, by designing a targeted therapy with RARβ agonists and chromatin remodelling therapeutic agents, the preclinical data suggest that it is conceivable to restore retinoid sensitivity in retinoid-resistant tumours with partial RARβ promoter methylation. This evidence concerns the gene RARB and neoplasm.